ASCO Annual Meeting | Conference

Axillary Radiotherapy Equal to Surgery in Early Breast Cancer

June 6th 2013

Women with early sentinel lymph node-positive breast cancer achieve as much of a disease-free and survival benefit from axillary radiotherapy as they do from axillary lymph node dissection with significantly less risk of lymphedema.

Dr. Churpek on Gene Mutations in Breast Cancer

June 6th 2013

Jane E. Churpek, MD, discusses a study that found the inherited mutations in breast cancer genes in African American breast cancer patients were revealed by targeted genomic capture and next-generation sequencing.

Dr. Shastri on Vinegar as a Cervical Cancer Screening Tool

June 6th 2013

Surendra Srinivas Shastri, MD, Professor, Preventive Oncology, Tata Memorial Hospital, Mumbai, India, discusses the results of a study looking at vinegar (acetic acid) as a cervical cancer screening tool.

Dr. Shaw Describes LDK378 in ALK-Positive Lung Cancer

June 5th 2013

Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital Cancer Center, discusses the clinical activity of the ALK inhibitor LDK378 in patients with non-small cell lung cancer harboring an ALK alteration.

Dr. Herbst on the Emergence of Immunotherapy in Cancer

June 5th 2013

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, describes the emergence of immunotherapy as a treatment in multiple types of cancer that was highlighted at the 2013 ASCO Annual Meeting.

Optimal Paclitaxel Schedule Identified for Early-Stage Breast Cancer

June 4th 2013

Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer.

Dr. Hudis Highlights Two Abstracts From ASCO 2013

June 4th 2013

Clifford A. Hudis, MD, ASCO President-Elect, describes the focus on global medicine at the 2013 American Society of Clinical Oncology Annual Meeting.

Vinegar Proves to Be Effective, Widely Implementable Cervical Cancer Screening Tool

June 4th 2013

A simple visual screening test using vinegar has the potential to dramatically reduce the number of deaths from cervical cancer in the developing world, according to findings from a large study in India, where use of the screening tool yielded a 31% reduction in cervical cancer mortality.

Drug Shortages Adversely Affect Treatment Decisions

June 3rd 2013

Shortages of cancer drugs caused many oncologists and hematologists to choose suboptimal treatment plans for their patients last year, and government efforts have done little to boost the availability of the hard-to-find medications.

More Evidence for 10-Years of Tamoxifen in ER+ Breast Cancer

June 3rd 2013

A British study has confirmed that 10 years of adjuvant tamoxifen substantially reduces late breast cancer recurrence and mortality among women with estrogen receptor-positive disease.

Dr. Gilbert Describes Ongoing RTOG 0825 Trial Analyses

June 3rd 2013

Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

Bevacizumab Improves Survival in Advanced Cervical Cancer

June 3rd 2013

Bevacizumab combined with either of two chemotherapy backbones improved overall survival by 3.7 months versus chemotherapy alone in patients with advanced cervical cancer.

Dr. Ribas on Anti-PD-1 Agent Lambrolizumab in Melanoma

June 3rd 2013

Antoni Ribas, MD, PhD, from UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

Dr. Ramalingam Reviews the GALAXY-1 Trial Results

June 3rd 2013

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, describes results from the phase II GALAXY-1 trial that explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma.

Sorafenib Doubles PFS in Rare Thyroid Cancer

June 3rd 2013

Interim findings from a randomized, global, phase III study indicate that the multi-targeted drug sorafenib nearly doubled PFS for patients with differentiated thyroid cancer resistant to radioactive iodine therapy.

First-Line Bevacizumab Does Not Improve Survival in Glioblastoma

June 2nd 2013

Adding bevacizumab to a standard treatment regimen for glioblastoma consisting of chemoradiation with temozolomide in newly diagnosed patients does not improve OS and did not significantly improve PFS.

Richard Gray on a Longer Duration of Tamoxifen

June 2nd 2013

Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

Dr. Brose on Sorafenib in RAI-Resistant Thyroid Cancer

June 2nd 2013

Marcia Brose, MD, PhD, from the Abramson Cancer Center at the University of Pennsylvania, discusses the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.

GM-CSF Boosts Ipilimumab Efficacy in Metastatic Melanoma

June 2nd 2013

Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.

Dr. Heinemann Reviews the FIRE-3 Trial Results

June 2nd 2013

Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.